Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]
- Market Cap ₹ 9,850 Cr.
- Current Price ₹ 1,297
- High / Low ₹ 1,619 / 690
- Stock P/E 36.8
- Book Value ₹ 167
- Dividend Yield 0.35 %
- ROCE 28.2 %
- ROE 22.5 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 22.3%
Cons
- Stock is trading at 7.81 times its book value
- The company has delivered a poor sales growth of 4.38% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
108 | 123 | 166 | 240 | 231 | 342 | 427 | 537 | 528 | 483 | 528 | 529 | 630 | |
97 | 101 | 132 | 183 | 169 | 248 | 284 | 348 | 321 | 269 | 308 | 308 | 336 | |
Operating Profit | 11 | 22 | 34 | 57 | 63 | 94 | 142 | 189 | 207 | 214 | 220 | 220 | 294 |
OPM % | 10% | 18% | 20% | 24% | 27% | 27% | 33% | 35% | 39% | 44% | 42% | 42% | 47% |
2 | 2 | 3 | 3 | 3 | 13 | 23 | 35 | 66 | 19 | 56 | 99 | 82 | |
Interest | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 3 | 8 | 7 | 13 | 19 | 21 | 20 | 22 | 26 | 26 | 26 |
Profit before tax | 11 | 22 | 33 | 51 | 58 | 93 | 146 | 203 | 253 | 210 | 250 | 293 | 350 |
Tax % | 24% | 34% | 23% | 19% | 22% | 24% | 30% | 27% | 22% | 26% | 25% | 20% | |
8 | 14 | 26 | 41 | 45 | 70 | 102 | 148 | 198 | 156 | 188 | 234 | 268 | |
EPS in Rs | 1.08 | 1.89 | 3.39 | 5.42 | 6.00 | 9.30 | 13.53 | 19.59 | 26.13 | 20.65 | 24.79 | 30.86 | 35.31 |
Dividend Payout % | 37% | 26% | 24% | 18% | 20% | 16% | 15% | 11% | 10% | 15% | 16% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 4% |
3 Years: | 0% |
TTM: | 27% |
Compounded Profit Growth | |
---|---|
10 Years: | 40% |
5 Years: | 18% |
3 Years: | 6% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | 44% |
5 Years: | 31% |
3 Years: | 29% |
1 Year: | 81% |
Return on Equity | |
---|---|
10 Years: | 29% |
5 Years: | 27% |
3 Years: | 22% |
Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
Reserves | 19 | 29 | 47 | 79 | 113 | 185 | 280 | 417 | 585 | 744 | 915 | 1,125 | 1,251 |
7 | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | |
63 | 79 | 109 | 128 | 132 | 116 | 115 | 107 | 89 | 101 | 123 | 162 | 160 | |
Total Liabilities | 104 | 128 | 174 | 223 | 263 | 317 | 411 | 539 | 691 | 861 | 1,054 | 1,303 | 1,427 |
26 | 31 | 101 | 111 | 143 | 152 | 169 | 138 | 167 | 183 | 162 | 157 | 157 | |
CWIP | 13 | 51 | 25 | 31 | 0 | 3 | 15 | 9 | 4 | 1 | 3 | 43 | 36 |
Investments | 1 | 1 | 1 | 1 | 1 | 19 | 48 | 168 | 196 | 149 | 265 | 434 | 455 |
64 | 44 | 48 | 80 | 118 | 143 | 178 | 225 | 325 | 528 | 624 | 670 | 780 | |
Total Assets | 104 | 128 | 174 | 223 | 263 | 317 | 411 | 539 | 691 | 861 | 1,054 | 1,303 | 1,427 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
24 | 33 | 60 | 50 | 44 | 55 | 23 | 107 | 87 | 295 | 231 | 157 | |
-16 | -45 | -44 | -24 | -6 | -37 | -60 | -76 | -41 | -4 | -276 | -86 | |
-1 | -2 | -6 | -9 | -14 | -7 | -12 | -15 | -33 | -3 | -23 | -30 | |
Net Cash Flow | 6 | -14 | 10 | 17 | 24 | 12 | -49 | 16 | 13 | 287 | -68 | 41 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 25 | 2 | 0 | 0 | 11 | 3 | 74 | 85 | 151 | 74 | 37 | 61 |
Inventory Days | 26 | 40 | 29 | 36 | 56 | 50 | 58 | 36 | 34 | 47 | 76 | 95 |
Days Payable | 94 | 99 | 100 | 108 | 161 | 149 | 148 | 92 | 79 | 131 | 116 | 150 |
Cash Conversion Cycle | -43 | -58 | -72 | -72 | -94 | -95 | -16 | 30 | 107 | -10 | -2 | 6 |
Working Capital Days | -118 | -164 | -175 | -125 | -112 | -44 | 44 | 62 | 137 | 61 | 96 | 60 |
ROCE % | 30% | 50% | 60% | 64% | 60% | 56% | 58% | 55% | 48% | 30% | 29% | 28% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
9 May - Q4 post-results conference call invite is enclosed herewith.
- Board Meeting Intimation for Financial Results And Declaration Of Interim Dividend, If Approved By The Board. 9 May
-
General_Announcements
6 May - Press Release on Grant of INVIMA Approval
- Compliance Certificate As per Regulation 40 (10) Of The SEBI Listing Regulations 25 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT REC
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptPPTREC
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Oct 2019TranscriptPPT
Product Portfolio[1]
Presently, the company has a very wide portfolio of pharma products with 4,000+ registered products, 650+ formulations and presence in 36 therapeutic segments. It has minimal reliance for revenues on a single product/ therapeutic segment.